Orchid Chemicals and Pharmaceuticals Ltd is expecting its business to improve with the Corporate Debt Restructuring ( CDR) process getting completed in next few weeks. The company, which has been facing challenge due to liquidity crunch, working capital and ... Business Standard, 11 hours ago
Orchid net loss at Rs 200 cr - Business Standard India, 1 week ago
Orchid Chemicals net loss jumps to Rs.200 crore - PharmaBiz, 1 week ago
3 images for "orchid chemicals and pharmaceuticals"
Low on working capital and high on interest outgo, Chennai-based Orchid Chemicals and Pharmaceuticals has reported a net loss of Rs 200 crore for the quarter ended September 30 against a loss of Rs 19.9 crore in the corresponding period last fiscal. However, ...Business Line, 1 week ago
Orchid Chemicals & Pharmaceuticals said its net loss for the quarter ended September 2013 has widened to Rs 2,003.00. It reported a net loss of Rs 199.50 million in the same quarter previous year. Net sales for the quarter rose 15.13% to Rs 3,805.00 million, ...Myiris, 1 week ago
Pritesh Mehta, Senior Technical Analyst at IIFL feels that above Rs 54, Orchid Chemicals and Pharmaceuticals can hit the levels of Rs 58-59 in next couple of days.Money Control, 1 month ago
Related tags: Hospira, India, Orchid, APIs, In-house Related topics: Globalisation, Ingredients, APIs (active pharmaceutical ingredients) Hospira looking to secure in-house API production Related news: Hospira says it intends to up in-house ...In-Pharmatechnologist, 2 days ago
Even as the Union cabinet appears divided over the issue of FDI cap in the pharmaceutical sector, industry analysts argue against any cap since it would unlikely to result in any major change in prices of essential drugs in the country. They argue ...DNA India, 1 week ago Govt to review FDI policy in pharma sector on Monday Economic Times, 2 weeks ago Government to review FDI policy in pharma sector on Monday: report NDTV Profit, 2 weeks ago
New Delhi: Rejecting the proposal by the Commerce and Industry Ministry, the Cabinet has decided not to lower the FDI limit for existing pharmaceutical firms. The Department of Industrial Policy and Promotion (DIPP), under the ministry, proposed ...NDTV Profit, 1 week ago Govt rejects proposal to lower FDI cap in existing pharma cos New Delhi Pioneer, 1 week ago
NEW DELHI: The Union cabinet on Thursday deferred a decision on a contentious proposal that seeks to prevent multinational companies from taking control of existing critical care drug companies, following strong opposition from key stakeholder ...Economic Times, 1 week ago Under pressure, cabinet defers decision on FDI curbs in pharma Economic Times, 1 week ago
Faced with rush of multinationals to acquire Indian pharma firms, the commerce and industry ministry is proposing to tighten the FDI policy for the sector by incorporating conditions like mandatory investment in R&D and non-compete clause in the ...Smart Investor, 3 weeks ago DIPP for stringent conditions in FDI in existing pharma cos Business Standard India, 3 weeks ago Commerce Ministry for more stringent FDI norms in pharma: report NDTV Profit, 3 weeks ago
More from: , Economic Times...and 1 other sources
Reportbuyer.com just published a new market research report: Report Details Contracted drug production - discover trends and segments with highest revenue potential Where's outsourced pharma manufacturing heading? Visiongain's updated report ...PRWeb, 4 weeks ago Antibiotics Partnering Terms and Agreements PR Newswire, 2 weeks ago Molecular Diagnostics - Global Strategic Business Report Asian Hospital & Healthcare Management, 1 month ago
on your WebpageAdd Widget >Get your members hooked!